Table of Contents

company-logo

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Immunome Dividend Announcement

• Immunome does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Immunome dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Immunome Dividend History

Immunome Dividend Yield

Immunome current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Immunome stock? Use our calculator to estimate your expected dividend yield:

Immunome Financial Ratios

P/E ratio-2.20
PEG ratio0.02
P/B ratio3.12
ROE-139.72%
Payout ratio0.00%
Current ratio6.17
Quick ratio6.17
Cash Ratio3.94

Immunome Dividend FAQ

Does Immunome stock pay dividends?
Immunome does not currently pay dividends to its shareholders.
Has Immunome ever paid a dividend?
No, Immunome has no a history of paying dividends to its shareholders. Immunome is not known for its dividend payments.
Why doesn't Immunome pay dividends?
There are several potential reasons why Immunome would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Immunome ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Immunome has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Immunome a dividend aristocrat?
Immunome is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Immunome a dividend king?
Immunome is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Immunome a dividend stock?
No, Immunome is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Immunome stocks?
To buy Immunome you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Immunome stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.